Adaptation and validation of the Mexican Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)

Jesús Cajigas-Silva, Neuroendocrinology Service, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”, Mexico City, Mexico
Jeanette Thorpe, Galen Research Ltd, Manchester, United Kingdom
Isobel Spray, Galen Research Ltd, Manchester, United Kingdom
Mariusz T. Grzeda, Galen Research Ltd, Manchester, United Kingdom
Lesly A. Portocarrero-Ortiz, Neuroendocrinology Service, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”, Mexico City, Mexico

Background: Growth hormone deficiency (GHD), caused by decreased secretion of growth hormone by the pituitary, has clinical repercussions that impact body composition, metabolic parameters, and can have a negative impact on quality of life. The Quality of Life in Adults with Growth Hormone Deficiency (QoL-AGHDA) is a patient-reported outcome measure used to assess the quality of life of adults with GHD. Objective: The objective of this study was to validate the QoL-AGHDA for use in Mexico. Materials and methods: First phase: Translation of the QoL-AGHDA into Spanish as spoken in Mexico. Face and content validity were assessed through 10 Cognitive debriefing interviews. Second phase: The Mexican version of the QoL-AGHDA was administered to 40 patients on two occasions for subsequent analysis. The distributional properties of the measure were explored through descriptive statistics. Cronbach’s α was calculated for internal consistency, and Spearman’s correlation coefficient was used to assess reliability. Results: The QoL-AGHDA for Mexicans showed high internal consistency, with Cronbach’s α coefficients of 0.91 and 0.92. Test-retest reliability was excellent, with a Spearman’s correlation coefficient of 0.95. Conclusion: The Mexican adaptation of the QoL-AGHDA demonstrated good psychometric properties, supporting its use in future studies to assess quality of life in adults with GHD in Mexico.

Keywords: Adaptation. Validation. Adult growth hormone deficiency. Quality of life. QoL-adult growth hormone deficiency.